ChiCTR1800019014
尚未开始
/
/
/
2018-10-19
/
/
青光眼
利用下一代蛋白質組學技術鑑定淚膜中青光眼的生物標誌物
利用下一代蛋白質組學技術鑑定淚膜中青光眼的生物標誌物
利用下一代蛋白質組學技術鑑定淚膜中青光眼的生物標誌物
病例对照研究
诊断试验新技术
N/A
N/A
N/A
/
14
/
1990-01-01
1990-01-01
/
Control group subject inclusion criteria: 1. Chinese adults aged between 40-60 years; 2. Spectacle corrected monocular VA: 0.2 logMAR or better after full correction; 3. No contact lens wear; 4. Free of ocular and systemic abnormalities e.g. cataract, diabetes mellitus (DM) Intraocular pressure (IOP): 21 mmHg or less in both eyes; 5. Difference in IOP between two eyes: 3 mmHg or less; 6. Able to give written consent. Newly diagnosed glaucoma group subject inclusion criteria: 1. Early onset of signs of primary open-angled glaucoma (POAG) 2. Intraocular pressure (IOP): 22 mmHg or more in one or both eyes; 3. Sign of optic nerve abnormalities according to the classification of Mild or Early Stage Glaucoma in the Glaucoma ICD-10 quick reference guide of the American Academy of Ophthalmology (AAO); 4. Free from other ocular and systemic diseases e.g. cataract, DM etc.; 5. Able to give written consent.；
登录查看1. Regular contact lens wear; 2. DM, severe heart disease, history of stroke; 3. Dry eye disease; 4. Underwent LASIK surgery.；
登录查看The Chinese University of Hong Kong
/
昌郁医药2024-11-22
上海和誉生物医药科技有限公司2024-11-22
云顶新耀2024-11-22
金斯瑞生物2024-11-22
细胞与基因治疗领域2024-11-22
肝脏时间2024-11-22
医药笔记2024-11-22
生物安全情报网2024-11-22
医药速览2024-11-22
亚盛医药2024-11-22
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科
